Journal of the American Academy of Dermatology最新文献_第5页

Evaluating Patient's Ability to Detect Changes in Hair Density Using Standardized Global Scalp Photography: A Cross-Sectional Study.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-08 DOI: 10.1016/j.jaad.2025.03.010

Christina S Oh, Nnaemeka Anyanwu, Michael G Buontempo, Deesha Desai, Ambika Nohria, Jerry Shapiro, Kristen Lo Sicco

引用次数: 0

Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-07 DOI: 10.1016/j.jaad.2025.01.089

Kenneth B Gordon, Matthias Augustin, Jonathan Barker, Yayoi Tada, Mark G Lebwohl, Ming Tang, Patrick Hofmann, Christian Thoma, Alice B Gottlieb

{"title":"Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study.","authors":"Kenneth B Gordon, Matthias Augustin, Jonathan Barker, Yayoi Tada, Mark G Lebwohl, Ming Tang, Patrick Hofmann, Christian Thoma, Alice B Gottlieb","doi":"10.1016/j.jaad.2025.01.089","DOIUrl":"10.1016/j.jaad.2025.01.089","url":null,"abstract":"Background: Generalized pustular psoriasis (GPP) is a chronic inflammatory disease with an unpredictable disease course. Long-term treatment goals include sustained resolution of skin symptoms, prevention of new flares, and improvement in quality of life (QoL).Objective: To compare the effect of the interleukin-36 receptor monoclonal antibody spesolimab 600 mg subcutaneous (SC) loading dose (LD) followed by 300 mg SC every 4 weeks (q4w) versus placebo on skin symptoms and QoL burden in patients with GPP.Methods: A post hoc analysis of the EFFISAYIL 2 trial (NCT04399837) was conducted to assess the proportion of patients with sustained improvement of skin symptoms (GPP Physician Global Assessment total score, 0 or 1) and QoL burden (Dermatology Life Quality Index score, 0 or 1) at all visits up to week 48.Results: Among the patients who received spesolimab 600 mg SC LD followed by 300 mg SC q4w, 63.3% had sustained improvement of skin symptoms (vs 29.0%; placebo), and 24.1% had sustained improvement of QoL burden (vs 3.2%; placebo).Limitations: Retrospective, descriptive, post hoc analysis.Conclusion: Spesolimab 600 mg SC LD followed by 300 mg SC q4w provides sustained improvement of skin symptoms and QoL burden in a substantially higher proportion of patients with GPP versus placebo.","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter from the editor: Improving outcomes for patients with central centrifugal cicatricial alopecia (CCCA).

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-07 DOI: 10.1016/j.jaad.2025.03.002

Dirk M Elston

引用次数: 0

Is TikTok the new Google? Content and Source Analysis of Google and TikTok as Search Engines for Dermatologic Content in 2024.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-06 DOI: 10.1016/j.jaad.2024.10.131

Andrea Quartey, Jules B Lipoff

引用次数: 0

Letter from the editor: Desmoplastic melanoma behaves differently from other melanomas-American Joint Committee on Cancer staging should differ.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-06 DOI: 10.1016/j.jaad.2025.03.001

Dirk M Elston

引用次数: 0

Sofpironium topical gel, 12.45%, for the treatment of axillary hyperhidrosis: pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-05 DOI: 10.1016/j.jaad.2025.02.086

David Pariser, Dee Anna Glaser, James Del Rosso, Neal Bhatia, Deirdre Hooper, Mark S Nestor, Stacy Smith, Joel Schlessinger, Adelaide Hebert, Patricia S Walker

{"title":"Sofpironium topical gel, 12.45%, for the treatment of axillary hyperhidrosis: pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies.","authors":"David Pariser, Dee Anna Glaser, James Del Rosso, Neal Bhatia, Deirdre Hooper, Mark S Nestor, Stacy Smith, Joel Schlessinger, Adelaide Hebert, Patricia S Walker","doi":"10.1016/j.jaad.2025.02.086","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.02.086","url":null,"abstract":"Background: Current treatments for primary axillary hyperhidrosis are insufficient for some patients. Sofpironium topical gel is a retrometabolically-designed topical anticholinergic with rapid metabolism, which is associated with reduced side effects and targeted efficacy.Objective: To assess efficacy and safety of sofpironium topical gel for primary axillary hyperhidrosis.Methods: Cardigan I and Cardigan II were double-blind, randomized, controlled pivotal phase 3 studies of sofpironium topical gel, 12.45%, versus vehicle gel (1:1 randomization) for daily application to the axillae for 6 weeks.Results: The combined Phase 3 studies included 353 subjects in the treatment groups and 348 subjects in the control groups. For the co-primary endpoint of ≥2-point improvement from baseline to end of treatment on Hyperhidrosis Disease Severity Measure-Axillary-7, pooled analyses showed significantly better results for treatment versus control (p<0.0001). For the pooled co-primary endpoint of gravimetric sweat production at treatment end, the treatment group had greater reduction in sweat production (p=0.0002). Secondary endpoints also showed a statistically significant benefit for sofpironium topical gel versus control. Treatment was well-tolerated.Limitations: Short treatment and follow-up periods.Conclusion: Sofpironium topical gel, 12.45%, applied topically once daily before bedtime is effective and well-tolerated for treatment of primary axillary hyperhidrosis in patients ≥9 years old.","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient risk factors and poor outcomes associated with multiple inpatient dermatology consultations in one year: A retrospective cohort study.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-05 DOI: 10.1016/j.jaad.2025.02.088

Emma Hansen, Abraham M Korman, Kristopher Fisher, Catherine G Chung, Benjamin H Kaffenberger, Rachel M Kirven

引用次数: 0

Use of the Connor-Davidson Resilience Scale in a Complex Medical Dermatology Clinic: Cross-sectional study evaluating associations between resilience, Health-related Quality of Life and Mental Health.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-04 DOI: 10.1016/j.jaad.2025.02.082

Caroline J Stone, Eliza Broadbent, Vikram N Sahni, Laurel Gray, Jennie T Clarke, Christopher B Hansen, Jamie L W Rhoads, John J Zone, Christopher M Hull, Yelena P Wu, Jacob Kean, Aaron M Secrest, Zachary H Hopkins

引用次数: 0

Effect of prednisone plus either adalimumab or cyclosporine on dermatological symptoms in Vogt-Koyanagi-Harada disease: systemic outcomes from a randomized trial.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-03 DOI: 10.1016/j.jaad.2025.02.081

Zhenyu Zhong, Jiayi Wang, Weiting Liao, Junjie Xiang, Tao Cai, Peizeng Yang

{"title":"Effect of prednisone plus either adalimumab or cyclosporine on dermatological symptoms in Vogt-Koyanagi-Harada disease: systemic outcomes from a randomized trial.","authors":"Zhenyu Zhong, Jiayi Wang, Weiting Liao, Junjie Xiang, Tao Cai, Peizeng Yang","doi":"10.1016/j.jaad.2025.02.081","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.02.081","url":null,"abstract":"Background: Vogt-Koyanagi-Harada (VKH) disease causes vitiligo, poliosis, and alopecia.Objective: To investigate the effect of prednisone plus either adalimumab or cyclosporine-based immunosuppression on VKH dermatological disorders using ancillary data from a VKH eye disease trial.Methods: Patients with VKH disease treated with individualized prednisone tapering (maximum daily dose, 40 mg; maximum duration, 6 months) were randomized to adjunctive adalimumab (N=54) or cyclosporine (N=56). Outcomes included changes in vitiligo, poliosis, and alopecia at month 6.Results: Overall, there was a decrease in the percentage of alopecia but no change in the presence of vitiligo or poliosis at month 6. The adalimumab group showed no nominally significant differences in the percentage changes of each dermatological manifestation but a greater reduction in the number of affected dermatological categories compared with the cyclosporine group.Limitations: This is a secondary analysis of a VKH eye disease trial. Six-month follow-up may not fully assess effects on vitiligo and poliosis.Conclusions: In conjunction with prednisone tapering, both adalimumab and cyclosporine similarily improved alopecia but had no obvious effect on the presence of vitiligo or poliosis at 6 months. Adalimumab was associated with a greater decrease in the number of affected dermatological conditions compared with cyclosporine.","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Melanoma-specific and overall survival in patients with single versus multiple primary melanoma: a national database study.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-03 DOI: 10.1016/j.jaad.2025.02.084

Tejas P Joshi, Piya Malhan, Natalie Garcia, Ida F Orengo

引用次数: 0